Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 63 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
BellaVie from Sambreville, company number BE0713976121, closed financial year 2025 with a result of € -155,860 after tax. For that financial year BellaVie recorded a gross margin of € 144,665 and equity of € 105,456. Compared with financial year 2024, the result moved from € -322,188 to € -155,860. The company made a loss. The buffer shrank hard: equity is 60 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 105,456
▼ 60% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -155,860
▲ 52 % less loss than in 2024
Profit after tax over the fiscal year.
€ 48,146
▼ 50% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.4 million.
People and assets in 2025
4.4
▲ 1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 233,916
▲ 30% vs 2024
€ 53,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 845
▼ 29% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 626,568
▲ 8% vs 2024
€ 551,568 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.
€ 208,436
▼ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 19,256
▲ € 18,886 vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 113,038 | € -279,024 | € -196,845 | € 144,665 | ▲ € 341,510 |
| Profit after taxes | € 1,768 | € -499,297 | € -322,188 | € -155,860 | ▲ € 166,328 |
| Equity | € 127,811 | € 260,504 | € 261,316 | € 105,456 | ▼ 60% |
| Total debts | € 491,698 | € 654,956 | € 942,017 | € 901,059 | ▼ 4% |
| Cash | € 92,441 | € 161,620 | € 96,137 | € 48,146 | ▼ 50% |
| Retained profit | € -380,954 | € -880,251 | € -1,202,439 | € -1,358,299 | ▼ € 155,860 |
| Bank debt | € 250,000 | € 172,959 | € 581,289 | € 626,568 | ▲ 8% |
| Balance sheet total | € 619,508 | € 915,459 | € 1,203,334 | € 1,006,515 | ▼ 16% |
| Employees (FTE) | 2.8 | 3.7 | 3.4 | 4.4 | ▲ 1 |
Key figures of BellaVie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to BellaVie?
What happened at BellaVie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 155,860. Source: NBB ↗
- New establishment in Sambreville. KBO
- Stratex became a director. NBB
- Baudouin Van Male Ghorain became a director. NBB
- Pierre Geerts became a director. NBB
- Yves Colinet became a director. NBB
- Dario Dalla Valle became a director. NBB
- Sibelex became a director. NBB
In short
From € 1,768 profit in 2022 to € 155,860 loss in 2025.
Best year ever: 2022, with € 1,768 profit.
On average € 32,900 of value added per employee in 2025.
A new publication or filing at BellaVie? We notify you, reason included.
Follow BellaVieDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of SIBELEX comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BellaVieBehind BellaVie are Stratex, Baudouin Van Male Ghorain, Pierre Geerts, Yves Colinet, Dario Dalla Valle and Sibelex. The shares are held by SIBELEX (1.5%).
Directors
According to the 2025 annual accounts
Administrator-manager · represented by Olivier Raimont
since 2023
Baudouin Van Male Ghorain
Director
since 2023
Pierre Geerts
Director
since 2023
Yves Colinet
Director
since 2023
Dario Dalla Valle
Director
since 2023
Shareholders
1.5%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Sainte Eugénie(TAM) 42
5060 Sambreville
Rue Sainte Eugénie(TAM) 40
5060 Sambreville
Active since 1 December 2024
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0713.976.121
- VAT number
- BE 0713.976.121
- Registered office
- Rue Sainte Eugénie(TAM) 42, 5060 Sambreville
- Names & denominations
- BellaVie
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 November 2018
- Peppol
- Active · Active since 20 Nov 2020
- Contact
- [email protected] +32475489983
- Activities · NACE
Groothandel in andere voedingsmiddelen, neg
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van gehomogeniseerde voedingspreparaten en dieetvoeding
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
+1